Abbott Laboratories (NYSE: ABT) has a price-to-earnings ratio that is above its average at 34.59x. and a 36-month beta value of 0.68. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 5 as “overweight,” 7 as “hold,” and 0 as “sell.”
The average price predicted for Abbott Laboratories (ABT) by analysts is $124.02, which is $23.2 above the current market price. The public float for ABT is 1.73B, and at present, short sellers hold a 0.66% of that float. On September 18, 2023, the average trading volume of ABT was 4.60M shares.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
ABT) stock’s latest price update
Abbott Laboratories (NYSE: ABT)’s stock price has decreased by -0.89 compared to its previous closing price of 102.65. However, the company has seen a 1.00% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-17 that Abbott’s adjusted diluted EPS payout ratio is going to expand significantly from the mid-30% range in 2022 to the mid-40% range in 2023. Reduced demand for COVID-19 testing saw the healthcare company’s revenue and adjusted diluted EPS shrink in the first half of 2023. Abbott’s interest coverage ratio was just shy of 30 through the first six months of 2023.
ABT’s Market Performance
Abbott Laboratories (ABT) has seen a 1.00% rise in stock performance for the week, with a -2.67% decline in the past month and a -3.12% plunge in the past quarter. The volatility ratio for the week is 1.54%, and the volatility levels for the past 30 days are at 1.59% for ABT. The simple moving average for the last 20 days is -1.30% for ABT stock, with a simple moving average of -4.34% for the last 200 days.
ABT Trading at -4.33% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.16% of loss for the given period.
Volatility was left at 1.59%, however, over the last 30 days, the volatility rate increased by 1.54%, as shares sank -3.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.09% lower at present.
During the last 5 trading sessions, ABT rose by +1.00%, which changed the moving average for the period of 200-days by -3.46% in comparison to the 20-day moving average, which settled at $102.92. In addition, Abbott Laboratories saw -7.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Wainer Andrea F, who sale 10,400 shares at the price of $105.03 back on Aug 08. After this action, Wainer Andrea F now owns 65,027 shares of Abbott Laboratories, valued at $1,092,297 using the latest closing price.
STARKS DANIEL J, the Director of Abbott Laboratories, sale 50,000 shares at $113.76 during a trade that took place back on Jul 27, which means that STARKS DANIEL J is holding 6,775,316 shares at $5,688,189 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- +19.16 for the present operating margin
- +51.14 for the gross margin
The net margin for Abbott Laboratories stands at +15.82. The total capital return value is set at 15.19, while invested capital returns managed to touch 13.00. Equity return is now at value 14.10, with 7.00 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 48.92 points at debt to equity in total, while total debt to capital is 32.85. Total debt to assets is 24.11, with long-term debt to equity ratio resting at 42.16. Finally, the long-term debt to capital ratio is 28.31.
When we switch over and look at the enterprise to sales, we see a ratio of 4.58, with the company’s debt to enterprise value settled at 0.09. The receivables turnover for the company is 6.87 and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To sum up, Abbott Laboratories (ABT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
